GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mangalam Drugs & Organics Ltd (BOM:532637) » Definitions » EBIT

Mangalam Drugs & Organics (BOM:532637) EBIT : ₹169 Mil (TTM As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Mangalam Drugs & Organics EBIT?

Mangalam Drugs & Organics's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was ₹49 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was ₹169 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Mangalam Drugs & Organics's annualized ROC % for the quarter that ended in Sep. 2024 was 16.10%. Mangalam Drugs & Organics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 10.11%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Mangalam Drugs & Organics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 6.63%.


Mangalam Drugs & Organics EBIT Historical Data

The historical data trend for Mangalam Drugs & Organics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mangalam Drugs & Organics EBIT Chart

Mangalam Drugs & Organics Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 127.48 458.40 349.35 - -6.65

Mangalam Drugs & Organics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -83.87 33.51 43.71 43.33 48.66

Competitive Comparison of Mangalam Drugs & Organics's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Mangalam Drugs & Organics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mangalam Drugs & Organics's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mangalam Drugs & Organics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mangalam Drugs & Organics's EV-to-EBIT falls into.



Mangalam Drugs & Organics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹169 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mangalam Drugs & Organics  (BOM:532637) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Mangalam Drugs & Organics's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=189.184 * ( 1 - -124.18% )/( (0 + 2634.772)/ 1 )
=424.1126912/2634.772
=16.10 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3641.107 - 920.348 - ( 165.217 - max(0, 1923.711 - 2009.698+165.217))
=2634.772

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Mangalam Drugs & Organics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=194.62/( ( (0 + max(0, 0)) + (1307.886 + max(616.818, 0)) )/ 1 )
=194.62/( ( 0 + 1924.704 )/ 1 )
=194.62/1924.704
=10.11 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(256.384 + 1429.526 + 147.55) - (920.348 + 0 + 296.294)
=616.818

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Mangalam Drugs & Organics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=169.208/2550.735
=6.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mangalam Drugs & Organics EBIT Related Terms

Thank you for viewing the detailed overview of Mangalam Drugs & Organics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Mangalam Drugs & Organics Business Description

Traded in Other Exchanges
Address
P. D'Mello Road, Rupam Building, 3rd Floor, No. 239, Near General Post Office, Mumbai, MH, IND, 400001
Mangalam Drugs & Organics Ltd is an Indian company operating in the healthcare sector. The company is engaged in the research and development and manufacturing of drugs. Its product range includes Active Pharmaceutical Ingredients (APIs), Intermediates, and Specialty chemicals. Its sales comprise sales in the Indian and overseas markets. The single operating segment of the company is the Manufacturing of Bulk Drugs.

Mangalam Drugs & Organics Headlines

No Headlines